Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates

Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs)Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of…